Active central nervous system (CNS) metastases.Xx_NEWLINE_xXPatients must not have known central nervous system metastasis or a history of central nervous system (CNS) metastases; patients with leptomeningeal disease are not eligibleXx_NEWLINE_xXPatients must not be known to have AML in the central nervous system (CNS)Xx_NEWLINE_xXPatients with central nervous system (CNS) disease are not eligibleXx_NEWLINE_xXCentral nervous system (CNS) metastases .Xx_NEWLINE_xXPresence of central nervous system (CNS) involvement requiring active treatmentXx_NEWLINE_xXSymptomatic or progressing or steroid requiring Central Nervous System (CNS) involvement disease at least four weeks prior to randomizationXx_NEWLINE_xXKnown central nervous system (CNS) involvementXx_NEWLINE_xXSubjects with inactive central nervous system (CNS) metastasis are eligible..Xx_NEWLINE_xXKnown central nervous system (CNS) disease, except for treated asymptomatic CNS metastasesXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXPatients with a known central nervous system (CNS) involvement of lymphoma are not eligible (CNS staging not required)Xx_NEWLINE_xXKnown central nervous system (CNS) leukemia.Xx_NEWLINE_xXLeukemia with active central nervous system (CNS) involvementXx_NEWLINE_xXCentral nervous system (CNS) involvement with disease refractory to intrathecal chemotherapyXx_NEWLINE_xXAML patients with active central nervous system (CNS) disease will be excluded.Xx_NEWLINE_xXActive central nervous system (CNS) involvement by leukemiaXx_NEWLINE_xXSymptomatic, untreated, or actively progressing central nervous system (CNS) metastases;Xx_NEWLINE_xXCurrent or past history of central nervous system (CNS) disease, or CNS involvement by MMXx_NEWLINE_xXActive extramedullary AML in testes or central nervous system (CNS)Xx_NEWLINE_xXSymptomatic central nervous system (CNS) metastases or primary CNS lymphomaXx_NEWLINE_xXActive or untreated central nervous system (CNS) metastasesXx_NEWLINE_xXKnown central nervous system (CNS) disease, except for treated asymptomatic CNS metastasesXx_NEWLINE_xXPrimary central nervous system (CNS) malignancy or CNS metastases.Xx_NEWLINE_xXKnown active central nervous system (CNS) involvement by lymphoma, including parenchymal and/or lymphomatous meningitisXx_NEWLINE_xXHistory or evidence of uncontrollable central nervous system (CNS) diseaseXx_NEWLINE_xXActive, untreated central nervous system (CNS) metastasisXx_NEWLINE_xXSubject has known current central nervous system (CNS) diseaseXx_NEWLINE_xXPresence of any active central nervous system (CNS) disease at the time of evaluation (parenchymal or leptomeningeal)Xx_NEWLINE_xXPrimary central nervous system (CNS) malignancy, or untreated/active CNS metastasesXx_NEWLINE_xXCentral nervous system (CNS) involvementXx_NEWLINE_xXKnown central nervous system (CNS) disease, except for treated asymptomatic CNS metastasesXx_NEWLINE_xXCentral nervous system (CNS) lymphoma or leptomeningeal infiltrationXx_NEWLINE_xXSymptomatic central nervous system (CNS) involvement or lymphangitic metastasis. Stable or improving CNS disease that is not under active treatment after receipt of adequate therapy is allowed.Xx_NEWLINE_xXPatients with known central nervous system (CNS) involvement of lymphoma are not eligibleXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXEvidence of leukemic meningitis or other central nervous system (CNS) involvement by leukemiaXx_NEWLINE_xXActive, uncontrolled central nervous system (CNS) involvement by lymphomaXx_NEWLINE_xXPatients must not have known central nervous system (CNS) involvement of lymphomaXx_NEWLINE_xXPatient with active central nervous system (CNS) metastasis or with history of CNS metastasisXx_NEWLINE_xXKnown active uncontrolled or symptomatic Central Nervous System (CNS) metastasesXx_NEWLINE_xXActive central nervous system (CNS) disease at time of screening.Xx_NEWLINE_xXSymptomatic central nervous system (CNS) malignancy or metastasis.Xx_NEWLINE_xXPatients with primary central nervous system (CNS) cancer.Xx_NEWLINE_xXPatients with known active central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvementXx_NEWLINE_xXHave active central nervous system (CNS) leukemiaXx_NEWLINE_xXAny untreated central nervous system (CNS) lesion.Xx_NEWLINE_xXActive or untreated central nervous system (CNS) metastasesXx_NEWLINE_xXCurrent central nervous system (CNS) lymphoma or leptomeningeal infiltration.Xx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXHas clinical signs of central nervous system (CNS) involvement of MM.Xx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXKnown active central nervous system (CNS) involvement by lymphoma should be excluded from this clinical trialXx_NEWLINE_xXParticipants with known central nervous system (CNS) leukemia involvement should be excluded from this clinical trial; patients with a history of CNS leukemia that has been treated and is no longer active as judged by the treating investigator are eligibleXx_NEWLINE_xXCentral nervous system (CNS) metastases (brain or leptomeningeal)Xx_NEWLINE_xXSymptomatic or untreated central nervous system (CNS) metastasesXx_NEWLINE_xXSymptomatic central nervous system (CNS) metastases.Xx_NEWLINE_xXActive central nervous system (CNS) disease.Xx_NEWLINE_xXCentral Nervous System (CNS) involvement with multiple myeloma defined as csf positivity for plasma cells or a parenchymal CNS plasmacytomaXx_NEWLINE_xXPresence of symptomatic or untreated central nervous system (CNS) metastasesXx_NEWLINE_xXKnown central nervous system (CNS) involvement by lymphomaXx_NEWLINE_xXPatients must have no clinical evidence of central nervous system (CNS) or pulmonary leukostasis, disseminated intravascular coagulation, or CNS leukemiaXx_NEWLINE_xXActive central nervous system (CNS) leukemiaXx_NEWLINE_xXUntreated central nervous system (CNS) metastasesXx_NEWLINE_xXActive central nervous system (CNS) or leptomeningeal metastasis (brain metastases)Xx_NEWLINE_xXActive central nervous system (CNS) involvement with leukemiaXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXCentral nervous system (CNS) tumorsXx_NEWLINE_xXHave symptomatic central nervous system (CNS) malignancy or metastasis.Xx_NEWLINE_xXUntreated, symptomatic Central nervous system (CNS) metastasesXx_NEWLINE_xXCentral nervous system (CNS) diseaseXx_NEWLINE_xXActive central nervous system (CNS) involvement by malignancy, except in cases of virus-associated malignancies with CNS involvement in which case the patient may benefit from the transplant to control the malignancyXx_NEWLINE_xXActive extramedullary AML in testes or central nervous system (CNS)Xx_NEWLINE_xXActive, uncontrolled central nervous system (CNS) disease including CNS leukemiaXx_NEWLINE_xXCentral nervous system (CNS) metastases or seizure disorderXx_NEWLINE_xXCentral nervous system (CNS) involvement by lymphoma/leukemiaXx_NEWLINE_xXPresence of central nervous system (CNS) lymphomaXx_NEWLINE_xXPatients with active known central nervous system (CNS) involvement of CLL or lymphoma; (patients with history of CNS CLL or lymphoma now in remission are eligible for the trial)Xx_NEWLINE_xXKnown central nervous system (CNS) involvement by malignancyXx_NEWLINE_xXUncontrolled metastatic disease to the brain or central nervous system (CNS).Xx_NEWLINE_xXPresence of active untreated central nervous system (CNS) leukemiaXx_NEWLINE_xXKnown central nervous system (CNS) involvement with CLL or T-LGLXx_NEWLINE_xXPresence of central nervous system (CNS) disease, which is symptomaticXx_NEWLINE_xXPrior therapy for central nervous system (CNS) lymphoma\r\n* Steroids not an exclusionXx_NEWLINE_xXActive, uncontrolled central nervous system (CNS) leukemia involvementXx_NEWLINE_xXPatients must not have evidence of active central nervous system (CNS) diseaseXx_NEWLINE_xXSubject has known active central nervous system (CNS) involvement from AMLXx_NEWLINE_xXActive central nervous system (CNS) involvement by lymphoma, including untreated symptomatic epidural diseaseXx_NEWLINE_xXActive central nervous system (CNS) or extramedullary diseaseXx_NEWLINE_xXPatients with active central nervous system (CNS) disease or history of brain metastases are excluded from studyXx_NEWLINE_xXLeptomeningeal carcinomatosis or other central nervous system (CNS) metastasesXx_NEWLINE_xXCentral nervous system (CNS) metastasis.Xx_NEWLINE_xXPrior central nervous system (CNS) involvement by tumor cells;Xx_NEWLINE_xXPresence of known central nervous system (CNS) leukemia.Xx_NEWLINE_xXKnown central nervous system (CNS) lymphoma or leukemiaXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXPatients with symptomatic central nervous system (CNS) metastases who are neurologically unstableXx_NEWLINE_xXPatients with active central nervous system (CNS) involvement with lymphoma are not eligibleXx_NEWLINE_xXUntreated central nervous system (CNS) metastasesXx_NEWLINE_xXPatients with active central nervous system (CNS) leukemia eligible at the discretion of treating physicianXx_NEWLINE_xXGENERAL: Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases.Xx_NEWLINE_xXKnown central nervous system (CNS) involvementXx_NEWLINE_xXActive or untreated central nervous system (CNS) metastases Exclusions Related to Cardiovascular DiseaseXx_NEWLINE_xXParticipant has known active central nervous system (CNS) involvement with AML.Xx_NEWLINE_xXKnown active uncontrolled or symptomatic Central Nervous System (CNS) metastases.Xx_NEWLINE_xXPatients with known active central nervous system (CNS) disease, including leptomeningeal involvementXx_NEWLINE_xXActive central nervous system (CNS) involvement by malignancyXx_NEWLINE_xXSymptomatic, untreated, or actively progressing central nervous system (CNS) metastases.Xx_NEWLINE_xXSubjects with symptomatic central nervous system (CNS) disease which is not adequately controlledXx_NEWLINE_xXPatients with history of central nervous system (CNS) involvementXx_NEWLINE_xXActive central nervous system (CNS) metastases and/or leptomeningeal involvementXx_NEWLINE_xXSymptomatic, untreated, or actively progressing central nervous system (CNS) metastasesXx_NEWLINE_xXPatients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myelomaXx_NEWLINE_xXUncontrolled central nervous system (CNS) disease (for hematologic malignancies)Xx_NEWLINE_xXKnown central nervous system (CNS) involvementXx_NEWLINE_xXHave central nervous system disease (CNS) as follows:Xx_NEWLINE_xXActive central nervous system (CNS) involvement of leukemia (lumbar puncture not required to rule out CNS involvement if not suspected)Xx_NEWLINE_xXActive central nervous system (CNS) diseaseXx_NEWLINE_xXKnown primary central nervous system (CNS) malignancyXx_NEWLINE_xXHas known active central nervous system (CNS) metastases and/or carcinomatous meningitis and/or has known active central nervous system (CNS) leukemia involvementXx_NEWLINE_xXKnown active central nervous system (CNS) involvementXx_NEWLINE_xXActive, untreated central nervous system (CNS) metastasesXx_NEWLINE_xXKnown active central nervous system (CNS) involvement by MMXx_NEWLINE_xXThe toxicity profile of nivolumab in patients with disease involvement of the central nervous system (CNS) is unknownXx_NEWLINE_xXSubject has known active central nervous system (CNS) involvement with AMLXx_NEWLINE_xXPatients with a history of central nervous system disease must have no clinical or radiological evidence of central nervous system (CNS) disease at the time of protocol enrollment and with CNS toxicity =< grade 2; patients with seizure disorders may be enrolled if seizures are well controlledXx_NEWLINE_xXPresence of active and clinically relevant central nervous system (CNS) disorder;Xx_NEWLINE_xXKnown central nervous system (CNS) involvement by lymphomaXx_NEWLINE_xXEvidence of active central nervous system (CNS) involvementXx_NEWLINE_xXPresence of active and clinically relevant Central Nervous System (CNS) disorderXx_NEWLINE_xXknown active central nervous system (CNS) involvement by malignancy.Xx_NEWLINE_xXCentral nervous system (CNS) involvement, including lymphomatous meningitisXx_NEWLINE_xXActive central nervous system (CNS) or testicular involvement by leukemiaXx_NEWLINE_xXKnown active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myelomaXx_NEWLINE_xXPatients with active and/or untreated central nervous system (CNS) lymphoma will not be eligibleXx_NEWLINE_xXPatients with active, uncontrolled central nervous system (CNS) leukemia will not be eligibleXx_NEWLINE_xXActive central nervous system (CNS) leukemia at time of treatmentXx_NEWLINE_xXActive central nervous system (CNS) disorder or seizure disorder or known CNS disease or neurologic symptomatologyXx_NEWLINE_xXPrior central nervous system (CNS) involvement by tumor cellsXx_NEWLINE_xXPatients with known brain metastases, active infection, or untreated central nervous system (CNS) leukemiaXx_NEWLINE_xXActive central nervous system (CNS) disease in patient with history of CNS malignancy.Xx_NEWLINE_xXNo active central nervous system (CNS) metastatic disease. NOTE: Subjects with CNS involvement must meet ALL of the following to be eligible:Xx_NEWLINE_xXHistory of or known active central nervous system (CNS) involvement with AMLXx_NEWLINE_xXActive central nervous system (CNS) involvement or leptomeningeal involvementXx_NEWLINE_xXParticipant has known Central Nervous System (CNS) involvement with AML.Xx_NEWLINE_xXKnown central nervous system (CNS) leukemiaXx_NEWLINE_xXPatients with known active central nervous system (CNS) disease, including leptomeningeal involvementXx_NEWLINE_xXHistory of plasma cell leukemia or multiple myeloma (MM) central nervous system (CNS) involvementXx_NEWLINE_xXActive, untreated central nervous system (CNS) involvementXx_NEWLINE_xXPatients with known active uncontrolled central nervous system (CNS) leukemia.Xx_NEWLINE_xXActive central nervous system (CNS) metastases and CNS metastases as the only sites of diseaseXx_NEWLINE_xXActive central nervous system (CNS)-only involvement by malignancy (note: participants with secondary CNS involvement are allowed on study)Xx_NEWLINE_xXActive central nervous system (CNS) metastases.Xx_NEWLINE_xXSubjects with symptomatic Central Nervous System (CNS) metastasesXx_NEWLINE_xXPrimary central nervous system (CNS) lymphomaXx_NEWLINE_xXCentral nervous system (CNS) metastasisXx_NEWLINE_xXPatients with active central nervous system (CNS) disease or history of brain metastases are excluded from studyXx_NEWLINE_xXHas known active central nervous system (CNS) lymphomaXx_NEWLINE_xXPatients with active central nervous system (CNS) disease or history of brain metastases are excluded from studyXx_NEWLINE_xXActive uncontrolled central nervous system (CNS) metastasesXx_NEWLINE_xXKnown central nervous system (CNS) involvementXx_NEWLINE_xXPatients with current evidence of active central nervous system (CNS) leukemiaXx_NEWLINE_xXPatients with active central nervous system (CNS) involvement with lymphoma are not eligibleXx_NEWLINE_xXKnown cytopathologically confirmed central nervous system (CNS) infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required)Xx_NEWLINE_xXCentral nervous system (CNS) involvementXx_NEWLINE_xXUncontrolled central nervous system (CNS) involvement by tumor cells within the past 2 monthsXx_NEWLINE_xXHas known active central nervous system (CNS) lymphomaXx_NEWLINE_xXCentral nervous system (CNS) involvement by lymphomaXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXActive, uncontrolled central nervous system (CNS) diseaseXx_NEWLINE_xXPatients with known active uncontrolled central nervous system (CNS) leukemiaXx_NEWLINE_xXPatients with symptomatic, untreated central nervous system (CNS) metastases are not eligibleXx_NEWLINE_xXPatients with untreated brain metastases/central nervous system (CNS) disease will be excludedXx_NEWLINE_xXActive central nervous system (CNS) malignancyXx_NEWLINE_xXAbout to undergo palliative radiation for a symptomatic central nervous system (CNS) metastasisXx_NEWLINE_xXCentral nervous system (CNS) or meningeal involvement, or cord compression by the lymphoma; history of CNS lymphomaXx_NEWLINE_xXIf prior central nervous system (CNS) leukemia, it must be treated and in CNS CRXx_NEWLINE_xXCentral nervous system (CNS) involvementXx_NEWLINE_xXHistory of or active central nervous system (CNS) or peripheral nerve stimulation (PNS) involvementXx_NEWLINE_xXSymptomatic and refractory central nervous system (CNS) leukemiaXx_NEWLINE_xXPatients with central nervous system (CNS) metastases who are neurologically unstableXx_NEWLINE_xXActive leukemia in the central nervous system (CNS)Xx_NEWLINE_xXPatients must have no clinical evidence of central nervous system (CNS) or pulmonary leukostasis, disseminated intravascular coagulation, or CNS leukemiaXx_NEWLINE_xXPatients with active central nervous system (CNS) disease or history of brain metastases are excluded from studyXx_NEWLINE_xXActive central nervous system (CNS) disease in patient with history of CNS malignancyXx_NEWLINE_xXCentral nervous system (CNS) lymphomaXx_NEWLINE_xXPatients diagnosed with primary central nervous system (CNS) or with CNS metastases/involvement, at any time during the disease course, are excluded from the study.Xx_NEWLINE_xXPatient has central nervous system (CNS) metastases or seizure disorderXx_NEWLINE_xXPatients with clinical evidences of active central nervous system (CNS) disease at inclusionXx_NEWLINE_xXActive central nervous system (CNS) diseaseXx_NEWLINE_xXCentral nervous system (CNS) involvement by lymphoma (clinically or cytologically confirmed)Xx_NEWLINE_xXPatients must not have active central nervous system leukemia; patients with history of central nervous system (CNS) leukemia with no evidence of active CNS disease may be enrolled; maintenance intrathecal chemotherapy for adequately treated CNS involvement with leukemia is allowed with approval from the study supporterXx_NEWLINE_xXPatients with active central nervous system (CNS) involvement with malignancy; patients with prior CNS disease that has been effectively treated will be eligible providing treatment was > 4 weeks before enrollmentXx_NEWLINE_xXCentral nervous system (CNS) metastasisXx_NEWLINE_xXPatients with known central nervous system (CNS) involvementXx_NEWLINE_xXKnown brain metastases or central nervous system (CNS) involvementXx_NEWLINE_xXPatient with active central nervous system (CNS) diseaseXx_NEWLINE_xXHas known clinically active central nervous system (CNS) involvementXx_NEWLINE_xXKnown central nervous system (CNS) tumor involvementXx_NEWLINE_xXHistory of plasma cell leukemia or MM central nervous system (CNS) involvementXx_NEWLINE_xXPrimary central nervous system (CNS) tumors or solid tumors with CNS metastases as the only site of active diseaseXx_NEWLINE_xXParticipant has overt central nervous system (CNS) disease (CNS 3 status)Xx_NEWLINE_xXStable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowedXx_NEWLINE_xXPatients with active central nervous system (CNS) or epidural tumorXx_NEWLINE_xXActive central nervous system (CNS) or extramedullary diseaseXx_NEWLINE_xXEvidence of central nervous system (CNS) metastasesXx_NEWLINE_xXActive central nervous system (CNS) involvement within the previous 2 monthsXx_NEWLINE_xXActive central nervous system (CNS) disease.Xx_NEWLINE_xXActive central nervous system (CNS) involvement of the underlying malignancyXx_NEWLINE_xXPatients with central nervous system (CNS) tumors who are receiving steroids are eligibleXx_NEWLINE_xXActive or untreated central nervous system (CNS) metastasesXx_NEWLINE_xXCentral nervous system (CNS) involvementXx_NEWLINE_xXActive and/or untreated central nervous system (CNS) leukemiaXx_NEWLINE_xXNo active central nervous system (CNS) diseaseXx_NEWLINE_xXPatients with active central nervous system (CNS) diseaseXx_NEWLINE_xXPatients may NOT have evidence or symptoms of central nervous system (CNS) disease at the time of enrollmentXx_NEWLINE_xXKnown central nervous system (CNS) metastases requiring treatment, such as surgery, radiation or steroidsXx_NEWLINE_xXActive (symptomatic) central nervous system (CNS) metastasis.Xx_NEWLINE_xXActive central nervous system (CNS) neoplastic involvementXx_NEWLINE_xXKnown chronic or active viral infections of the central nervous system (CNS)Xx_NEWLINE_xXKnown cerebral metastases, central nervous system (CNS) or epidural tumorXx_NEWLINE_xXPresence of untreated and/or symptomatic central nervous system (CNS) metastasisXx_NEWLINE_xXConfirmed absence of central nervous system (CNS) diseaseXx_NEWLINE_xXActive central nervous system (CNS) diseaseXx_NEWLINE_xXPatients with history of extramedullary AML, except for central nervous system (CNS) involvement that is currently controlled, will not be eligible for enrollmentXx_NEWLINE_xXClinical evidence of active central nervous system (CNS) leukemia requiring active therapy; prior CNS leukemia well-controlled by ongoing therapy is allowedXx_NEWLINE_xXPatients with active central nervous system (CNS) diseaseXx_NEWLINE_xXCentral nervous system (CNS) metastases or seizure disorderXx_NEWLINE_xXNo uncontrolled seizure disorder, active neurological disease, or known central nervous system (CNS) diseaseXx_NEWLINE_xXActive central nervous system (CNS) involvement by malignancy; Note: Patients with history of CNS disease that has been effectively treated will be eligible provided that treatment was > 4 weeks before enrollmentXx_NEWLINE_xXPatients with active central nervous system (CNS) involvement by malignancy; patients with prior CNS disease that has been effectively treated will be eligible providing treatment was > 4 weeks before enrollmentXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXActive central nervous system (CNS) leukemiaXx_NEWLINE_xXKnown central nervous system (CNS) metastasesXx_NEWLINE_xXCentral nervous system (CNS) involvement within 3 monthsXx_NEWLINE_xXPatients with active central nervous system (CNS) or epidural tumorXx_NEWLINE_xXPatient must have no current or prior history of central nervous system (CNS) involvementXx_NEWLINE_xXPatients with central nervous system (CNS) disease are eligible for treatment only after their CNS disease has been directly addressed with radiation therapyXx_NEWLINE_xXHistory of primary central nervous system (CNS) disease that would interfere with subject evaluationXx_NEWLINE_xXKnown active central nervous system (CNS) involvementXx_NEWLINE_xXPatient with active central nervous system (CNS) diseaseXx_NEWLINE_xXNo evidence of extramedullary leukemia, such as central nervous system (CNS) or soft tissue involvementXx_NEWLINE_xXPatient with active central nervous system (CNS) involvementXx_NEWLINE_xXPresence of leukemia in the central nervous system (CNS)Xx_NEWLINE_xXNo current central nervous system (CNS) myeloma at time of enrollmentXx_NEWLINE_xXTumors arising outside of the central nervous system (CNS)Xx_NEWLINE_xXKnown clinically active central nervous system (CNS) or extramedullary AML, except leukemia cutis.Xx_NEWLINE_xXHave active central nervous system (CNS) leukemiaXx_NEWLINE_xXPatients with known central nervous system (CNS) involvementXx_NEWLINE_xXPresence of leukemia in the central nervous system (CNS)Xx_NEWLINE_xXPresence of central nervous system (CNS) diseaseXx_NEWLINE_xXCentral nervous system (CNS) involvement with disease refractory to intrathecal chemotherapyXx_NEWLINE_xXStable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowedXx_NEWLINE_xXActive central nervous system (CNS) leukemia at time of HCTXx_NEWLINE_xXPatients with known central nervous system (CNS) involvement by leukemiaXx_NEWLINE_xXPresence of central nervous system (CNS) metastasesXx_NEWLINE_xXEvidence of active extramedullary disease (including central nervous system [CNS] leukemia)Xx_NEWLINE_xXActive central nervous system (CNS) leukemia at time of HSCTXx_NEWLINE_xXPatients with central nervous system (CNS) malignancies.Xx_NEWLINE_xXClinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemiaXx_NEWLINE_xXActive or history of central nervous system (CNS) metastasesXx_NEWLINE_xXClinically active central nervous system (CNS) leukemia;Xx_NEWLINE_xXSymptomatic central nervous system (CNS) metastases who are neurologically unstableXx_NEWLINE_xXPatients with active central nervous system (CNS) involvement by malignant cellsXx_NEWLINE_xXHistory of asymptomatic or symptomatic central nervous system (CNS) metastasisXx_NEWLINE_xXPatients diagnosed with primary central nervous system (CNS) or with CNS metastases or involvement, at any time during the disease course, are excluded from the study.Xx_NEWLINE_xXActive central nervous system (CNS) disease in patient with history of CNS malignancyXx_NEWLINE_xXPatient with active central nervous system (CNS) metastasis or with history of CNS metastasisXx_NEWLINE_xXConcommitant therapy that includes other chemotherapy that is or may be active against ALL (except central nervous system [CNS] therapy)Xx_NEWLINE_xXSubjects with symptomatic, untreated metastases to the central nervous system (CNS) at the time of screening.Xx_NEWLINE_xXHistory of or known active central nervous system (CNS) involvement or leptomeningeal involvementXx_NEWLINE_xXSubjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study)Xx_NEWLINE_xXHas central nervous system (CNS) involvement of leukemia or a history of CNS leukemiaXx_NEWLINE_xXActive central nervous system (CNS) diseaseXx_NEWLINE_xXHistory of plasma cell leukemia or central nervous system (CNS) involvementXx_NEWLINE_xXKnown clinically active central nervous system (CNS) leukemiaXx_NEWLINE_xXKnown clinically active central nervous system(CNS) leukemiaXx_NEWLINE_xXPrimary central nervous system (CNS) lymphomaXx_NEWLINE_xXKnown central nervous system (CNS) lymphoma or leukemiaXx_NEWLINE_xXPatients with known or suspected central nervous system (CNS) leukemia are not eligibleXx_NEWLINE_xXEvidence of progressive or symptomatic central nervous system (CNS) metastases or leptomeningeal diseaseXx_NEWLINE_xXPresence of known, active central nervous system (CNS) metastasesXx_NEWLINE_xXActive central nervous system (CNS) disease – if a history of AML related CNS involvement, screening cerebrospinal fluid (CSF) analysis must be negativeXx_NEWLINE_xXHistory of central nervous system (CNS) metastasis.Xx_NEWLINE_xXActive leukemic central nervous system (CNS) diseaseXx_NEWLINE_xXPatient has a known or suspected primary central nervous system (CNS) tumor or CNS tumor involvement or active leptomeningeal disease.Xx_NEWLINE_xXSymptomatic or untreated central nervous system (CNS) metastasesXx_NEWLINE_xXKnown central nervous system (CNS) involvement with lymphoma.Xx_NEWLINE_xXPatient has distant metastatic disease, including central nervous system (CNS) tumor involvementXx_NEWLINE_xXHave clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia.Xx_NEWLINE_xXPatients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:Xx_NEWLINE_xXSymptomatic central nervous system (CNS) involvement by AMLXx_NEWLINE_xXUntreated central nervous system (CNS) involvementXx_NEWLINE_xXActive central nervous system (CNS) involvement or leptomeningeal metastases involvementXx_NEWLINE_xXPatients with symptomatic central nervous system (CNS) metastases.Xx_NEWLINE_xXPresence of symptomatic central nervous system (CNS) metastasesXx_NEWLINE_xXKnown active central nervous system (CNS) involvement with AML at study entryXx_NEWLINE_xXPatients with suspected central nervous system (CNS) involvement should undergo lumbar puncture; those with documented CNS involvement will be excludedXx_NEWLINE_xXPatients with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases are excludedXx_NEWLINE_xXSubject has known current central nervous system (CNS) diseaseXx_NEWLINE_xXCentral nervous system (CNS) metastases or seizure disorderXx_NEWLINE_xXPre-existing central nervous system (CNS) demyelination or seizure disordersXx_NEWLINE_xXSubjects must not have evidence of active leukemia in the central nervous system (CNS)Xx_NEWLINE_xXSymptomatic central nervous system (CNS) metastases requiring treatmentXx_NEWLINE_xXActive central nervous system (CNS) leukemiaXx_NEWLINE_xXCentral nervous system (CNS) toxicity =< grade 2Xx_NEWLINE_xXPatients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myelomaXx_NEWLINE_xXPatients with active central nervous system (CNS) malignancyXx_NEWLINE_xXUncontrolled central nervous system (CNS) disease involvementXx_NEWLINE_xXSymptomatic central nervous system (CNS) metastasis.Xx_NEWLINE_xXAML central nervous system (CNS) involvementXx_NEWLINE_xXKnown primary central nervous system (CNS) malignancy or symptomatic CNS metastasesXx_NEWLINE_xXHas known clinically active central nervous system (CNS) involvement OR history of resolved CNS involvement by multiple myelomaXx_NEWLINE_xXPatient has chronic or active viral infections of the central nervous system (CNS)Xx_NEWLINE_xXPatients with disease progression in the central nervous system (CNS) onlyXx_NEWLINE_xXPatients with active central nervous system (CNS) or epidural tumorXx_NEWLINE_xXPatients with central nervous system (CNS) involvement refractory to intrathecal chemotherapyXx_NEWLINE_xXPatients with active central nervous system (CNS) metastasesXx_NEWLINE_xXPatients with history of central nervous system (CNS) involvement or active CNS involvement by malignancyXx_NEWLINE_xXActive central nervous system (CNS) malignancy as defined by:\r\n* Lymphoma: tumor mass on computed tomography (CT) scan or leptomeningeal disease\r\n* Leukemia: CNS 2 or CNS 3 classificationXx_NEWLINE_xXPatients must have no known central nervous system (CNS) involvement by lymphomaXx_NEWLINE_xXActive or suspicion of central nervous system (CNS) leukemiaXx_NEWLINE_xXHistory of central nervous system (CNS) diseaseXx_NEWLINE_xXCentral nervous system (CNS) metastases that are symptomatic and/or requiring steroidsXx_NEWLINE_xXActive central nervous system (CNS) involvement by malignancyXx_NEWLINE_xXPatients must not have clinical evidence of central nervous system (CNS) involvement by lymphoma            \r\n* Any laboratory or radiographic tests performed to assess CNS involvement must be negative and must be performed within 42 days prior to registrationXx_NEWLINE_xXNo brain or central nervous system (CNS) metastasesXx_NEWLINE_xXUntreated or symptomatic central nervous system (CNS) metastasesXx_NEWLINE_xXActive Central nervous system (CNS) metastasesXx_NEWLINE_xXknown central nervous system (CNS) metastases that are untreated, symptomatic, or require steroids to control symptomsXx_NEWLINE_xXActive Central Nervous System (CNS) involvement by malignancyXx_NEWLINE_xXPrimary central nervous system (CNS) malignancy, or untreated/active CNS metastasesXx_NEWLINE_xXSubject has symptomatic and untreated central nervous system (CNS) diseaseXx_NEWLINE_xXPresence of or known history of brain/central nervous system (CNS) tumor or metastasesXx_NEWLINE_xXKnown and untreated, or active central nervous system (CNS) metastases (progressing or requiring treatment)Xx_NEWLINE_xXSymptomatic, untreated, or actively progressing central nervous system (CNS) metastasesXx_NEWLINE_xXPrimary disease involving the Central Nervous System (CNS)Xx_NEWLINE_xXHas known clinically active central nervous system (CNS) involvementXx_NEWLINE_xXHave active leukemic involvement of the central nervous system (CNS).Xx_NEWLINE_xXPrimary central nervous system (CNS) malignancy, or untreated/active CNS metastasesXx_NEWLINE_xXCentral nervous system (CNS) involvement by lymphoma/leukemiaXx_NEWLINE_xXKnown symptomatic central nervous system (CNS) metastasesXx_NEWLINE_xXProven Central Nervous System (CNS) leukemiaXx_NEWLINE_xXHas active central nervous system (CNS) or leptomeningeal metastasisXx_NEWLINE_xXParticipant has untreated central nervous system (CNS) metastases.Xx_NEWLINE_xXSubjects who have had clinical evidence of central nervous system (CNS) or pulmonary leukostasis, disseminated intravascular coagulation, or CNS leukemia.Xx_NEWLINE_xXUntreated or active/progressing Central Nervous system (CNS) metastasesXx_NEWLINE_xXKnown primary central nervous system (CNS) malignancy or symptomatic CNS metastases, except ATRTXx_NEWLINE_xXPatients who have symptomatic central nervous system (CNS) involvement are not eligibleXx_NEWLINE_xXPatients are ineligible if they have any history of central nervous system (CNS) metastasesXx_NEWLINE_xXHave symptomatic or non stable central nervous system (CNS) malignancy.Xx_NEWLINE_xXHistory of or active central nervous system (CNS) malignancyXx_NEWLINE_xXKnown primary central nervous system (CNS) malignancy or symptomatic CNS metastasesXx_NEWLINE_xXPatients with primary central nervous system (CNS) lymphomaXx_NEWLINE_xXActive central nervous system (CNS) involvement of diseaseXx_NEWLINE_xXKnown untreated or active central nervous system (CNS) metastasesXx_NEWLINE_xXSubject has uncontrolled metastases to the central nervous system (CNS).Xx_NEWLINE_xXActive/symptoms of central nervous system (CNS) diseaseXx_NEWLINE_xXPatients with known active uncontrolled central nervous system (CNS) leukemia.Xx_NEWLINE_xXEvidence for central nervous system (CNS) metastatic diseaseXx_NEWLINE_xXActive AML involvement of the central nervous system (CNS) with disease refractory to intrathecal chemotherapyXx_NEWLINE_xXCentral nervous system (CNS) involvement.Xx_NEWLINE_xXPatients with documented central nervous system (CNS) involvementXx_NEWLINE_xXActive central nervous system (CNS) metastases requiring treatmentXx_NEWLINE_xXSubject who has central nervous system (CNS) or meningeal involvement by lymphoma.Xx_NEWLINE_xXCentral nervous system (CNS) metastasis.Xx_NEWLINE_xXPrimary central nervous system (CNS) malignancy or active metastases within 5 yearsXx_NEWLINE_xXHave the presence of unstable central nervous system (CNS) metastasis.Xx_NEWLINE_xXHave symptomatic central nervous system (CNS) malignancy or metastasis (screening not required).Xx_NEWLINE_xXActive or untreated central nervous system (CNS) metastasisXx_NEWLINE_xXPatients with untreated or symptomatic central nervous system (CNS) metastasesXx_NEWLINE_xXEvidence of active central nervous system (CNS) leukemiaXx_NEWLINE_xXPatient has active or history of central nervous system (CNS) diseaseXx_NEWLINE_xXPatients with active central nervous system (CNS) involvement by malignancy; patients with prior CNS disease that has been effectively treated will be eligible providing treatment was > 4 weeks before enrollmentXx_NEWLINE_xXHave clinical evidence or a history of central nervous system (CNS) metastasisXx_NEWLINE_xXActive central nervous system (CNS) metastasesXx_NEWLINE_xXKnown untreated central nervous system (CNS) metastasisXx_NEWLINE_xXSymptomatic Central Nervous System (CNS) metastasisXx_NEWLINE_xXSubjects with active central nervous system (CNS) metastases are excludedXx_NEWLINE_xXParticipants with central nervous system (CNS) lymphomaXx_NEWLINE_xXAdequate central nervous system function defined as:\r\n* Patients with a history of central nervous system (CNS) disease must have no clinical or radiological evidence of CNS disease at the time of study enrollment\r\n* Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsants\r\n* CNS toxicity =< grade 2Xx_NEWLINE_xXPhase 1b: History or evidence of central nervous system (CNS) metastasesXx_NEWLINE_xXPatients with active/uncontrolled central nervous system (CNS) leukemiaXx_NEWLINE_xXActive central nervous system (CNS) disease at the time of treatmentXx_NEWLINE_xXPatient must have no known central nervous system (CNS) involvementXx_NEWLINE_xXActive central nervous system (CNS) or symptomatic epidural metastatic diseaseXx_NEWLINE_xXCentral nervous system (CNS) metastases or seizure disorderXx_NEWLINE_xXAML patients with known, active leptomeningeal/central nervous system (CNS) involvementXx_NEWLINE_xXActive central nervous system (CNS) leukemia or known CNS leukemia.Xx_NEWLINE_xXHistory of central nervous system (CNS) lymphoma or other CNS diseaseXx_NEWLINE_xXParticipants with active central nervous system (CNS) involvement are excluded; patients with suspected CNS disease should be worked up appropriately prior to enrollmentXx_NEWLINE_xXNo active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permittedXx_NEWLINE_xXPatients with active central nervous system (CNS) disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphomaXx_NEWLINE_xXCentral nervous system (CNS) leukemiaXx_NEWLINE_xXCentral nervous system (CNS) metastasisXx_NEWLINE_xXActive central nervous system (CNS) metastases.Xx_NEWLINE_xXKnown central nervous system (CNS) involvement by malignancyXx_NEWLINE_xXPatient has active or history of central nervous system (CNS) disease or meningeal involvementXx_NEWLINE_xXKnown primary central nervous system (CNS) malignancy or symptomatic or untreated CNS metastasesXx_NEWLINE_xXKnown cytopathologically confirmed central nervous system (CNS) infiltrationXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXNo active central nervous system (CNS) diseaseXx_NEWLINE_xXKnown central nervous system (CNS) involvementXx_NEWLINE_xXSymptomatic central nervous system (CNS) lymphoma involvementXx_NEWLINE_xXUntreated or symptomatic central nervous system (CNS) metastasesXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXActive central nervous system (CNS) involvement with leukemiaXx_NEWLINE_xXSymptomatic central nervous system (CNS) malignancy or metastasis.Xx_NEWLINE_xXPatients with central nervous system (CNS) tumors or known brain metastasesXx_NEWLINE_xXParticipant has known active central nervous system (CNS) involvement with AML.Xx_NEWLINE_xXPrior or concurrent central nervous system (CNS) metastasesXx_NEWLINE_xXKnown central nervous system (CNS) diseaseXx_NEWLINE_xXSubjects with known or suspected central nervous system (CNS) involvement are not eligibleXx_NEWLINE_xXPatients with known central nervous system (CNS) involvement are excluded from this clinical trialXx_NEWLINE_xXCentral nervous system (CNS) involvement by CLL.Xx_NEWLINE_xXAny past or current Central Nervous System (CNS) involvement, including leptomeningeal leukemia.Xx_NEWLINE_xXPatients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myelomaXx_NEWLINE_xXHistory of central nervous system (CNS) metastasis that are untreated or not stableXx_NEWLINE_xXHas evidence of uncontrolled central nervous system (CNS) involvement (previous radiation and off steroids is acceptable)Xx_NEWLINE_xXPatients with known active central nervous system (CNS) diseaseXx_NEWLINE_xXUntreated central nervous system (CNS) metastasesXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXCentral nervous system (CNS) metastasesXx_NEWLINE_xXCentral nervous system (CNS) disease, including treated brain metastasesXx_NEWLINE_xXCentral nervous system (CNS) involvement by lymphomaXx_NEWLINE_xXCentral nervous system (CNS) metastasesXx_NEWLINE_xXClinical evidence of active central nervous system (CNS) leukemiaXx_NEWLINE_xXKnown active or untreated central nervous system (CNS) metastasesXx_NEWLINE_xXPrimary central nervous system (CNS) lymphoma or known or suspected CNS involvement by non-primary CNS NHLXx_NEWLINE_xXHistory of central nervous system (CNS) involvement by myelomaXx_NEWLINE_xXKnown central nervous system (CNS) involvement of lymphomaXx_NEWLINE_xXSymptomatic, untreated, or actively progressing central nervous system (CNS) metastasesXx_NEWLINE_xXKnown central nervous system (CNS) involvementXx_NEWLINE_xXCentral nervous system (CNS) involvement of the patient's lymphomaXx_NEWLINE_xXNo known central nervous system (CNS) metastasesXx_NEWLINE_xXPatients with active central nervous system (CNS) involvement with lymphoma should be excluded from this clinical trialXx_NEWLINE_xXPatients with untreated central nervous system (CNS) or epidural tumorXx_NEWLINE_xXKnown history of central nervous system (CNS) metastasesXx_NEWLINE_xXSubjects with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia.Xx_NEWLINE_xXAny untreated central nervous system (CNS) lesionXx_NEWLINE_xXSymptomatic central nervous system (CNS) NHL.Xx_NEWLINE_xXSymptomatic central nervous system (CNS) disease.Xx_NEWLINE_xXKnown active central nervous system (CNS) malignancyXx_NEWLINE_xXPresence of untreated/active central nervous system (CNS) metastasesXx_NEWLINE_xXKnown cytopathologically confirmed central nervous system (CNS) infiltrationXx_NEWLINE_xXClinically unstable central nervous system (CNS) metastasisXx_NEWLINE_xXPatients with active central nervous system (CNS) involvement with malignancy; patients with prior CNS disease that has been effectively treated will be eligible providing treatment was > 4 weeks before enrollmentXx_NEWLINE_xXPatients with central nervous system (CNS) involvementXx_NEWLINE_xXClinical evidence of central nervous system (CNS) metastasis.Xx_NEWLINE_xXSymptomatic or untreated central nervous system (CNS) metastases requiring concurrent treatmentXx_NEWLINE_xXPatient must not have known central nervous system (CNS) leukemiaXx_NEWLINE_xXActive central nervous system (CNS) leukemiaXx_NEWLINE_xXAny Central Nervous System (CNS) metastases or history of CNS metastasesXx_NEWLINE_xXHematologic and primary central nervous system (CNS) malignanciesXx_NEWLINE_xXKnown clinically active central nervous system (CNS) leukemiaXx_NEWLINE_xXAny primary or active central nervous system (CNS) malignancy, including metastatic diseaseXx_NEWLINE_xXPresence of leukemia in the central nervous system (CNS)Xx_NEWLINE_xXKnown active Central Nervous System (CNS) lymphoma.Xx_NEWLINE_xXKnown central nervous system (CNS) involvementXx_NEWLINE_xXPatients with active and/or untreated central nervous system (CNS) leukemia will not be eligibleXx_NEWLINE_xXKnown central nervous system (CNS) metastasesXx_NEWLINE_xXKnown or suspected brain or other central nervous system (CNS) metastasesXx_NEWLINE_xXPatient with active central nervous system (CNS) involvement with lymphoid malignancyXx_NEWLINE_xXKnown central nervous system (CNS) involvement by lymphoma.Xx_NEWLINE_xXActive central nervous system (CNS) metastasesXx_NEWLINE_xXActive or prior central nervous system (CNS) leukemia, unless in complete remission for at least 3 monthsXx_NEWLINE_xXPresence of central nervous system (CNS) metastatic diseaseXx_NEWLINE_xXKnown cytopathologically confirmed central nervous system (CNS) infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required)Xx_NEWLINE_xXFor Dose Escalation (Part A): Have central nervous system (CNS) malignancy or metastasisXx_NEWLINE_xXUncontrolled central nervous system (CNS) involvement with diseaseXx_NEWLINE_xXActive central nervous system (CNS) diseaseXx_NEWLINE_xXPatients with stable, treated central nervous system (CNS) disease are eligibleXx_NEWLINE_xXActive central nervous system (CNS) leukemia at time of treatmentXx_NEWLINE_xXCentral nervous system (CNS) involvement with disease refractory to intrathecal chemotherapyXx_NEWLINE_xXHave active Central Nervous System (CNS) diseaseXx_NEWLINE_xXPrimary central nervous system (CNS) lymphomaXx_NEWLINE_xXKnown central nervous system (CNS) lymphoma involvementXx_NEWLINE_xXEvidence of AML central nervous system (CNS) involvementXx_NEWLINE_xXSubjects with symptomatic central nervous system (CNS) metastasesXx_NEWLINE_xXActive central nervous system (CNS) lymphomaXx_NEWLINE_xXCentral nervous system (CNS) involvement.Xx_NEWLINE_xXActive central nervous system (CNS) leukemiaXx_NEWLINE_xXCentral nervous system (CNS) involvement with disease refractory to intrathecal chemotherapyXx_NEWLINE_xXActive central nervous system (CNS) disease in patient with history of CNS malignancyXx_NEWLINE_xXActive diagnosis of central nervous system (CNS) involvement with CLLXx_NEWLINE_xXHistory or known presence of central nervous system (CNS) metastasesXx_NEWLINE_xXCentral Nervous System (CNS) disease only.Xx_NEWLINE_xXCentral nervous system (CNS) involvement with disease refractory to intrathecal chemotherapyXx_NEWLINE_xXActive central nervous system (CNS) involvement by malignancy (defined as CNS-3 per National Comprehensive Cancer Network [NCCN] guidelines)Xx_NEWLINE_xXActive central nervous system (CNS) diseaseXx_NEWLINE_xXActive central nervous system (CNS) or extramedullary malignant diseaseXx_NEWLINE_xXActive, symptomatic central nervous system (CNS) leukemia;Xx_NEWLINE_xXPatient has central nervous system metastatic involvement. Patients with previously treated CNS metastases are also excluded.Xx_NEWLINE_xXCentral nervous system (CNS) involvement of DLBCLXx_NEWLINE_xXPatients with known active central nervous system (CNS) leukemiaXx_NEWLINE_xXCurrent central nervous system (CNS) involvement by lymphomaXx_NEWLINE_xXSymptomatic central nervous system (CNS) lesions, or CNS lesions that require therapyXx_NEWLINE_xXPatients with symptomatic central nervous system (CNS) leukemia or patients with poorly controlled central nervous system leukemiaXx_NEWLINE_xXKnown central nervous system (CNS) involvementXx_NEWLINE_xXPatients with central nervous system (CNS) disease or testicular disease are eligibleXx_NEWLINE_xXActive central nervous system (CNS) leukemiaXx_NEWLINE_xXActive central nervous system (CNS) disease involvementXx_NEWLINE_xXKnown active central nervous system (CNS) leukemia.Xx_NEWLINE_xXPatients with symptomatic central nervous system (CNS) metastasesXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXCentral nervous system (CNS) lymphomaXx_NEWLINE_xXHave active central nervous system (CNS) metastasisXx_NEWLINE_xXClinically active central nervous system (CNS) cancer involvement. Imaging to exclude CNS involvement not required.Xx_NEWLINE_xXKnown cerebral metastases, central nervous system (CNS) or epidural tumorXx_NEWLINE_xXUncontrolled central nervous system (CNS) diseaseXx_NEWLINE_xXKnown active central nervous system (CNS) metastases.Xx_NEWLINE_xXPatients with known active central nervous system (CNS) leukemia will be excluded from this clinical studyXx_NEWLINE_xXKnown central nervous system (CNS) diseaseXx_NEWLINE_xXKnown active and uncontrolled central nervous system (CNS) involvement of leukemia (a lumbar puncture does not need to be performed as a part of screening)Xx_NEWLINE_xXSymptomatic central nervous system (CNS) involvementXx_NEWLINE_xXPatients with central nervous system (CNS) metastasis. Intrathecal chemotherapy is allowed for patients who require CNS prophylaxis or therapy.Xx_NEWLINE_xXActive or untreated central nervous system (CNS) metastasesXx_NEWLINE_xXActive or untreated central nervous system (CNS) lesionsXx_NEWLINE_xXHad evidence of active central nervous system (CNS) involvementXx_NEWLINE_xXPatients with active central nervous system (CNS) malignancy are not eligible for this trialXx_NEWLINE_xXActive central nervous system (CNS) lymphoma/leukemia - Patients with prior CNS involvement are eligible provided that it has been treated and is in remissionXx_NEWLINE_xXActive/symptoms of central nervous system (CNS) diseaseXx_NEWLINE_xXCentral nervous system (CNS) diseaseXx_NEWLINE_xXPatients with known symptomatic central nervous system (CNS) metastases requiring steroidsXx_NEWLINE_xXUntreated central nervous system (CNS) metastatic diseaseXx_NEWLINE_xXPresence of central nervous system (CNS) leukemia.Xx_NEWLINE_xXPatients are excluded if they have a history of central nervous system (CNS) metastasesXx_NEWLINE_xXUntreated brain or central nervous system (CNS) metastasesXx_NEWLINE_xXCentral nervous system (CNS) metastases or seizure disorderXx_NEWLINE_xXCentral Nervous System (CNS) Lymphoma or chronic immunosuppression-associated central nervous system (CNS) lymphoma.Xx_NEWLINE_xXSymptomatic central nervous system (CNS) involvementXx_NEWLINE_xXActive or untreated central nervous system (CNS) metastasesXx_NEWLINE_xXKnown central nervous system (CNS) or brain metastases.Xx_NEWLINE_xXPrimary central nervous system (CNS) lymphomaXx_NEWLINE_xXActive or untreated central nervous system (CNS) metastasesXx_NEWLINE_xXActive central nervous system (CNS) disease in patient with history of CNS malignancyXx_NEWLINE_xXPatients with documented central nervous system (CNS) diseaseXx_NEWLINE_xXActive or symptomatic central nervous system (CNS) disease or epidural involvementXx_NEWLINE_xXKnown untreated central nervous system (CNS) metastasisXx_NEWLINE_xXIf prior central nervous system (CNS) leukemia, it must be treated and in CNS complete remission (CR)Xx_NEWLINE_xXPrimary central nervous system (CNS) lymphomaXx_NEWLINE_xXKnown central nervous system (CNS) disease except for treated brain metastasisXx_NEWLINE_xXUntreated or active central nervous system (CNS) metastases.Xx_NEWLINE_xXSymptomatic, steroid-requiring or progressive central nervous system (CNS) involvementXx_NEWLINE_xXSymptomatic central nervous system (CNS) metastases requiring steroid useXx_NEWLINE_xXUntreated/active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)Xx_NEWLINE_xXActive involvement of the Central Nervous System (CNS).Xx_NEWLINE_xXPatients with active central nervous system (CNS) diseaseXx_NEWLINE_xXClinically uncontrolled central nervous system (CNS) involvementXx_NEWLINE_xXPatients with a history of central nervous system (CNS) malignancy.Xx_NEWLINE_xXPatients with central nervous system (CNS) metastatic involvement.Xx_NEWLINE_xXClinically uncontrolled central nervous system (CNS) involvementXx_NEWLINE_xXCurrent evidence of central nervous system (CNS) leukemiaXx_NEWLINE_xXCNS (Central Nervous System) tumors as well as history of brain metastasesXx_NEWLINE_xXKnown brain tumors or Central nervous system (CNS) metastasesXx_NEWLINE_xXPatients must have no clinical evidence of central nervous system (CNS) or pulmonary leukostasis, disseminated intravascular coagulation, or CNS leukemiaXx_NEWLINE_xXNo known central nervous system (CNS) metastases or neurological symptoms possibly related to active CNS metastasisXx_NEWLINE_xXHas a symptomatic central nervous system (CNS) tumor causing nausea and/or vomitingXx_NEWLINE_xXPatient has active or history of central nervous system (CNS) disease.Xx_NEWLINE_xXKnown central nervous system (CNS) involvementXx_NEWLINE_xXHistory of central nervous system (CNS) PTLDXx_NEWLINE_xXActive central nervous system (CNS) involvement of their malignancy.Xx_NEWLINE_xXFor participants with leukemia, has overt central nervous system (CNS) disease (CNS 3 status).Xx_NEWLINE_xXIf prior central nervous system (CNS) leukemia, it must be treated and have no evidence of CNS diseaseXx_NEWLINE_xXActive Central Nervous System [CNS] diseaseXx_NEWLINE_xXKnown primary central nervous system (CNS) tumors or brain metastasesXx_NEWLINE_xXKnown central nervous system (CNS) disease except for treated brain metastasesXx_NEWLINE_xXPatients with active central nervous system (CNS) lymphomaXx_NEWLINE_xXSymptomatic Central Nervous System (CNS) metastasesXx_NEWLINE_xXKnown untreated or active central nervous system (CNS) metastasesXx_NEWLINE_xXActive central nervous system (CNS) diseaseXx_NEWLINE_xXUntreated or active central nervous system (CNS) metastasesXx_NEWLINE_xXNo active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permittedXx_NEWLINE_xXKnown Central Nervous System (CNS) involvement by lymphoma.Xx_NEWLINE_xXHave symptomatic central nervous system (CNS) malignancy or metastasisXx_NEWLINE_xXCentral nervous system (CNS) metastases from lymphoma or small cell lung cancerXx_NEWLINE_xXPrimary central nervous system (CNS) malignancy or untreated/active CNS metastasesXx_NEWLINE_xXPresence of central nervous system (CNS) involvement with Hodgkin lymphomaXx_NEWLINE_xXb. Central nervous system (CNS) trauma or active seizure disorders requiring medicationXx_NEWLINE_xXThe patient was diagnosed with leukemic Central Nervous System (CNS) disease (e.g. before chemotherapy) or presents neurological symptoms at baseline suggestive of a CNS involvement.Xx_NEWLINE_xXUncontrolled central nervous system (CNS) involvement by tumor cellsXx_NEWLINE_xXPatients with active central nervous system (CNS) diseaseXx_NEWLINE_xXHistory of Central nervous system (CNS) or brain metastasesXx_NEWLINE_xXActive central nervous system (CNS) involvement by malignancyXx_NEWLINE_xXCentral nervous system (CNS) lymphomatous involvement or leptomeningeal lymphomaXx_NEWLINE_xXNo evidence of central nervous system (CNS) metastasesXx_NEWLINE_xXActive untreated central nervous system (CNS) metastasisXx_NEWLINE_xXKnown central nervous system (CNS) lymphoma, leptomeningeal lymphomaXx_NEWLINE_xXUntreated central nervous system (CNS) metastases.Xx_NEWLINE_xXUnstable metastases to the central nervous system (CNS)Xx_NEWLINE_xXPre-existing central nervous system (CNS) demyelination or seizure disordersXx_NEWLINE_xXActive MM involving the central nervous system (CNS).Xx_NEWLINE_xXHistory of central nervous system (CNS) involvementXx_NEWLINE_xXPatients with symptomatic Central Nervous System (CNS) metastasesXx_NEWLINE_xXKnown untreated central nervous system (CNS) metastasis; patients with CNS metastasis will be allowed on study once treatedXx_NEWLINE_xXActive central nervous system (CNS) leukemia or known chloromatous diseaseXx_NEWLINE_xXKnown presence of central nervous system (CNS) involvement by lymphomaXx_NEWLINE_xXActive central nervous system (CNS) disease (related to primary malignancy) at the time of enrollmentXx_NEWLINE_xXCentral nervous system (CNS) lymphoma; active brain or leptomeningeal metastases.Xx_NEWLINE_xXCentral nervous system (CNS) disease that is untreated, symptomatic, or requires therapy to control symptoms.Xx_NEWLINE_xXKnown central nervous system (CNS) involvementXx_NEWLINE_xXPatient has symptomatic primary or metastatic central nervous system (CNS) diseaseXx_NEWLINE_xXPatients with prior history of primary central nervous system (CNS) cancer or CNS metastasesXx_NEWLINE_xXNo active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permittedXx_NEWLINE_xXActive central nervous system (CNS) leukemiaXx_NEWLINE_xXDiagnosis of primary central nervous system (CNS) lymphomaXx_NEWLINE_xXKnown brain metastasis or primary central nervous system (CNS) malignancyXx_NEWLINE_xXComorbidities at particular risk (i.e., active central nervous system [CNS], active CNS metastases, hydrocephalus or coagulopathy)Xx_NEWLINE_xXHistory of central nervous system (CNS) tumorXx_NEWLINE_xXKnown primary central nervous system (CNS) malignancy or untreated or active CNS metastasesXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXHistory of Grade >= 2 central nervous system (CNS) hemorrhageXx_NEWLINE_xXKnown central nervous system (CNS) lymphomaXx_NEWLINE_xXPatients with central nervous system (CNS) lymphoma are not eligible for the trial unless the disease had been treated and the subject remains without symptoms with no active CNS lymphoma.Xx_NEWLINE_xXUncontrolled Central Nervous System (CNS) metastasesXx_NEWLINE_xXPatients with known central nervous system (CNS) involvementXx_NEWLINE_xXParticipants with known central nervous system (CNS) involvement of lymphomaXx_NEWLINE_xXSubjects with untreated Central nervous system (CNS) metastases are excludedXx_NEWLINE_xXPatient must not have active central nervous system (CNS) involvementXx_NEWLINE_xXActive central nervous system (CNS) diseaseXx_NEWLINE_xXActive central nervous system (CNS) disease (the action for acupuncture may be associated with central nervous system activity, and patients with CNS pathology may respond differently to treatment than the general population)Xx_NEWLINE_xXActive central nervous system (CNS) involvement by malignant cellsXx_NEWLINE_xXEXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Active involvement of the central nervous system with malignancy (previous central nervous system [CNS] involvement is allowed if clearance of CNS disease has been documented prior to enrollment)Xx_NEWLINE_xXUncontrolled central nervous system (CNS) disease (for hematologic malignancies)Xx_NEWLINE_xXActive central nervous system (CNS) involvement by malignant cellsXx_NEWLINE_xXClinical evidence of central nervous system (CNS) or pulmonary leukostasis, or CNS leukemiaXx_NEWLINE_xXActive central nervous system (CNS) involvement by malignant cellsXx_NEWLINE_xXActive central nervous system (CNS) involvement by malignant cellsXx_NEWLINE_xXPatient must not have untreated or symptomatic central nervous system (CNS) metastasisXx_NEWLINE_xXCentral nervous system (CNS) only disease on recent imagingXx_NEWLINE_xXClinical suspicion of active central nervous system (CNS) involvement by leukemiaXx_NEWLINE_xXKnown central nervous system (CNS) involvementXx_NEWLINE_xXKnown central nervous system (CNS) involvement by AMLXx_NEWLINE_xXHas presence of central nervous system (CNS) involvement of leukemia or a history of CNS leukemiaXx_NEWLINE_xXPatients must not have known central nervous system (CNS) involvementXx_NEWLINE_xXPatients with known central nervous system (CNS) involvementXx_NEWLINE_xXCentral nervous system (CNS) metastasesXx_NEWLINE_xXPatients with a history of symptomatic central nervous system (CNS) unless they have been treated and are asymptomatic.Xx_NEWLINE_xXKnown active or suspected central nervous system (CNS) leukemia.Xx_NEWLINE_xXKnown central nervous system (CNS) involvement of lymphoma (CNS staging not required)Xx_NEWLINE_xXHave symptomatic central nervous system (CNS) malignancy or metastasis.Xx_NEWLINE_xXCriteria 6, Active or untreated central nervous system (CNS) metastases per CT or MRI evaluation during screeningXx_NEWLINE_xXClinical signs of central nervous system (CNS) involvement of MM.Xx_NEWLINE_xXSuspected central nervous system (CNS) tumor(s) or sarcoma.Xx_NEWLINE_xXSubjects with symptomatic brain metastasis or central nervous system (CNS) diseaseXx_NEWLINE_xXKnown active central nervous system (CNS) leukemia.Xx_NEWLINE_xXKnown central nervous system (CNS) lymphoma or leukemiaXx_NEWLINE_xX